: the solution to better protecting the world against diseases
ProLNG is Progeneer’s proprietary cholesterol capped toll-like receptor 7/8 agonist with ProLoNGed immune response.
Due to their ability to activate antigen presenting cells and to enhance both humoral and cellular immune response, TLR7/8 agonists have long been demonstrated potential as vaccine adjuvants in pre-clinical and clinical settings. Studies with conventional TLR7/8 agonists, such as resiquimod (R848), however, demonstrated high toxicity from rapid systemic exposure limiting their widespread use.
In ProLNG, the active site of TLR7/8 agonist molecule is blocked by cholesterol through a cleavable linker thereby overcoming the limitations of previous compounds. The active site is only released under certain conditions allowing a delayed and prolonged immune response. With the cholesterol capping, ProLNG can be easily formulated in lipid nanoparticles (LNPs) or liposomes.
The feasibility of ProLNG in LNPs or liposomes and its delayed and prolonged activation of the TLR7/8 pathway makes ProLNG highly applicable as vaccine adjuvants against infectious diseases and anticancer therapy. ProLNG can be especially useful with mRNA vaccines where the delayed activation of adjuvant activity does not interfere with the translation process.
: providing transformative solutions to difficult-to-treat respiratory diseases
ProSN is a Surfactant Nanoparticle engineered to deliver negatively charged therapeutic proteins or nucleic acids such as mRNA or siRNA through the inhalation route. The ProSN liposomal carrier contains protamine, a positively charged FDA approved protein, pulmonary surfactant proteins SP-B and SP-C, and a cargo of interest.
Pulmonary surfactant proteins SP-B and SP-C are hydrophobic membrane proteins important for the fluidity of the surfactant. The presence of these naturally-derived proteins helps the unloading of the cargo from the liposome at the alveoli region, where pulmonary surfactants are rich.
Unlike conventional pulmonary surfactant liposomes, ProSN is able to efficiently entrap negatively charged particles to the liposome. The cargo of interest can be directly delivered to the alveoli region conferring high pulmonary drug concentration and low systemic exposure.
ProSN can be applied to difficult-to-treat respiratory conditions such as severe viral pneumonia, idiopathic pulmonary fibrosis, cancer, etc.
